BioCentury
ARTICLE | Company News

Portola, Bayer deal

February 8, 2016 8:00 AM UTC

Portola partnered with Bayer to include Bayer’s Xarelto rivaroxaban in Japanese clinical trials of Portola’s andexanet alfa. Portola will receive $5 million up front and is eligible for an undisclosed milestone payment upon Japanese approval of andexanet alfa as an antidote for Xarelto. Bayer will fund clinical studies in Japan of andexanet alfa and Xarelto. ...